Disease · MONDO_0002514
hepatobiliary neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. hepatobiliary neoplasm. Diseases, record MONDO_0002514. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002514
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
hepatic and biliary neoplasms, hepatic and biliary tumors, hepatic and biliary tumours, hepatic, biliary, and gallbladder neoplasms, hepato-biliary neoplasm, hepato-biliary tumor, hepato-biliary tumour, hepatobiliary system neoplasm, hepatobiliary system neoplasm (disease), hepatobiliary system tumor, hepatobiliary system tumour, hepatobiliary tumor, hepatobiliary tumors, hepatobiliary tumour, hepatobiliary tumours, liver and biliary neoplasm, liver and biliary system neoplasm, neoplasm of hepatobiliary system, tumor of hepatobiliary system, tumour of hepatobiliary system
- Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AZACITIDINE | CHEMBL1489 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OLUTASIDENIB | CHEMBL4297610 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LENVATINIB | CHEMBL1289601 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REGORAFENIB | CHEMBL1946170 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVOCERANIB | CHEMBL3186534 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SORAFENIB | CHEMBL1336 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets37
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Unknown | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor inhibitor | Unknown | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor inhibitor | Unknown | https://conductscience.org/library/genes/2324 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 2 | Serine/threonine-protein kinase B-raf inhibitor | Unknown | https://conductscience.org/library/genes/673 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Unknown | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 2 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Unknown | https://conductscience.org/library/genes/5159 | Drugs and targets |
| RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 2 | Serine/threonine-protein kinase RAF inhibitor | Unknown | https://conductscience.org/library/genes/5894 | Drugs and targets |
| RET | Proto-oncogene tyrosine-protein kinase receptor Ret | 2 | Tyrosine-protein kinase receptor RET inhibitor | Unknown | https://conductscience.org/library/genes/5979 | Drugs and targets |
| ABL1 | Tyrosine-protein kinase ABL1 | 1 | Tyrosine-protein kinase ABL inhibitor | Unknown | https://conductscience.org/library/genes/25 | Drugs and targets |
| DDR2 | Discoidin domain-containing receptor 2 | 1 | Discoidin domain-containing receptor 2 inhibitor | Unknown | https://conductscience.org/library/genes/4921 | Drugs and targets |
1 to 10 of 37
See all 37 targetsTrials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03684811 | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Phase 1/2 | 93 | 2023-01-25 | Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations | AZACITIDINE, CISPLATIN, GEMCITABINE, NIVOLUMAB, OLUTASIDENIB | Its record names the disease | ClinicalTrials.gov |
| NCT03892577 | Real-world Study for Patients With Advanced Hepatobiliary Tumors | 3,000 | Objective Response Rate, Progression-free Survival, Overall Survival, Disease Control Rate, Duration of Response, Five-year Survival Rate, Quality of Life | LENVATINIB, REGORAFENIB, RIVOCERANIB, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials16
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002514
GET https://conductscience.org/api/diseases/v1/MONDO_0002514/targets?page=2